Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET.

The U.S. Food and Drug Administration assigned taletrectinib’s New Drug Application with a Prescription Drug User Fee Act goal date of June 23, 2025.

Investors and the general public are invited to listen to a live webcast of the call at https://investors.nuvationbio.com/investors/. Materials related to the call will be available prior to the start of the conference call. A replay of the webcast will be available after the conference call concludes.

About Nuvation Bio

Nuvation Bio is a global oncology company focused on solving some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib, a third-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor.

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250422970092/en/

Nuvation Bio Investor Contact:

ir@nuvationbio.com

Nuvation Bio Media Contact:

media@nuvationbio.com

Source: Nuvation Bio Inc.

FAQ

When is Nuvation Bio (NUVB) releasing Q1 2025 earnings?

Nuvation Bio will release Q1 2025 earnings on Wednesday, May 7, 2025, with a conference call scheduled for 4:30 p.m. ET.

What is the PDUFA date for Nuvation Bio's taletrectinib?

The FDA has set a PDUFA goal date of June 23, 2025, for taletrectinib's New Drug Application.

How can investors access Nuvation Bio's Q1 2025 earnings call?

Investors can access the live webcast through Nuvation Bio's investor relations website at https://investors.nuvationbio.com/investors/.

What will be discussed in Nuvation Bio's Q1 2025 earnings call?

The call will cover Q1 2025 financial results, program updates, and the commercial strategy for taletrectinib.